Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Dr Lalchandani Labs Ltd
Your Vote -
Buy
25.00%
Hold
25.00%
Sell
50.00%
25.00%
4 users have voted
Option Chain
Analyzes market sentiment, predicts Dr Lalchandani Labs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Dr. Lalchandani Labs - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
-
Dr. Lalchandani Labs - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Dr. Lalchandani Labs - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
-
Dr. Lalchandani Labs - Reply To The Clarification Sought By BSE
-
Dr. Lalchandani Labs - Clarification sought from Dr Lalchandani Labs Ltd
-
Dr. Lalchandani Labs has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Dr. Lalchandani Labs - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Dr. Lalchandani Labs has submitted to BSE the Shareholding Pattern for the Period Ended March 02, 2026
-
Dr. Lalchandani Labs - Approval Of Basis Of Allotment Under Right Issue
-
Dr. Lalchandani Labs - Board Meeting Outcome for Outcome Of Board Meeting Held On Monday March 02, 2026
-
Dr. Lalchandani Labs - Board Meeting Revised Outcome For Extension Of Issue Period
-
Dr. Lalchandani Labs - Board Meeting Outcome for Board Meeting Outcome For Extension Of Issue Period
Key fundamentals
Evaluate the intrinsic value of Dr Lalchandani Labs Ltd stock
| Name | March-25 | March-24 | March-23 | March-22 | March-21 |
|---|---|---|---|---|---|
| Assets | 14.0242 | 12.9424 | 13.6059 | 14.527 | 12.9481 |
| Liabilities | 14.0242 | 12.9424 | 13.6059 | 14.527 | 12.9481 |
| Equity | 4.3331 | 4.3331 | 4.3331 | 4.3331 | 4.333 |
| Gross Profit | 0.9233 | 0.1996 | 0.0834 | 2.406 | 2.2186 |
| Net Profit | 0.4172 | 0.6175 | -1.5628 | 0.9333 | 1.0113 |
| Cash From Operating Activities | 0.3671 | -0.218 | -0.0013 | 2.0056 | 1.1879 |
| NPM(%) | 9.36 | 12.83 | -31 | 8.27 | 10.34 |
| Revenue | 4.4538 | 4.8095 | 5.0402 | 11.2787 | 9.7799 |
| Expenses | 3.5305 | 4.6099 | 4.9568 | 8.8727 | 7.5613 |
| ROE(%) | 2.88 | 4.26 | -10.78 | 6.44 | 6.98 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Dr Lalchandani Labs Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 760.60 | 4.63 | 45.05 | 5.90 | 301.39 | 0.66 |
| Lotus Eye Hospital and Institute Ltd | 119.35 | 2.49 | 375.45 | 21.48 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 17.33 | -0.97 | 0.00 | 44.60 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 673.35 | -5.05 | 0.00 | 20.26 | -363.15 | 0.00 |
Company Info
The Company was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by M/s Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017. The Corporate Identification Number of the Company is U85320DL2017PLC321605.MAJOR EVENTS AND MILESTONES2017- Incorporation of the Company in the name and style of "Dr Lalchandani Labs Limited" to takeover the Existing Partnership Firm.- Entered into an Agreement for takeover of the Existing partership Firm named on going concern basis Dr A Lalchandani Pathology Laborataries2018- Entered in to an Agreement for purchase of acquiring office premises at J-23, Block-J, Lajpat Nagar-III, New Delhi for consideration other than cash from promoter, Mr. Arjan Lal Chandani.
The Company was originally incorporated as partnership firm at New Delhi vide Partnership Agreement dated 15th Day of September, 2011 in the name of Dr. A Lalchandani Pathology Laboratories. Thereafter, the Partnership Firm was taken over by M/s Dr Lalchandani Labs Limited incorporated under the provisions of Companies Act, 2013 vide certificate of Incorporation dated 2nd August, 2017 issued by the Registrar of Companies, Delhi vide agreement dated 31st August, 2017. The Corporate Identification Number of the Company is U85320DL2017PLC321605.MAJOR EVENTS AND MILESTONES2017- Incorporation of the Company in the name and style of "Dr Lalchandani Labs Limited" to takeover the Existing Partnership Firm.- Entered into an Agreement for takeover of the Existing partership Firm named on going concern basis Dr A Lalchandani Pathology Laborataries2018- Entered in to an Agreement for purchase of acquiring office premises at J-23, Block-J, Lajpat Nagar-III, New Delhi for consideration other than cash from promoter, Mr. Arjan Lal Chandani.
Read More
Parent Organisation
Dr. Lalchandani Labs Ltd.
Founded
02/08/2017
Managing Director
Dr.Arjan Lal Chandani
NSE Symbol
FAQ
The current price of Dr Lalchandani Labs Ltd is
The 52-week high for Dr Lalchandani Labs Ltd is
The market capitalization of Dr Lalchandani Labs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Dr Lalchandani Labs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Dr Lalchandani Labs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Dr Lalchandani Labs Ltd shares.
The CEO of Dr Lalchandani Labs Ltd is Dr.Arjan Lal Chandani, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
